Re: Otras Aventuras de los Farmas USA
GAS
Tengo el pálpito de que hoy cerramos por encima de los 2'80$. Lo que no quita para que me sume a las dos yoyas al japo claro :-D
GAS
Tengo el pálpito de que hoy cerramos por encima de los 2'80$. Lo que no quita para que me sume a las dos yoyas al japo claro :-D
Tan dificil es que para Abril-Mayo estemos con el GAS a $3.5 ?
Yo es que no lo veia tan dificil pero esta claro que no hay que fiarse....
GAS
Yo no solo lo veo dificil sino que lo veo muy probable. Pero claro es palabra de pillado. Ya estamos en 2'80$ ;-P
Los brokers suelen tener una opción que es "todo o nada".
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Vaya velas le meten en cuestion de segundos. Esto vale lo que 4 quieren que valga. Ni el tiempo, ni la produccion ni el tecnico....nada vale.
GAS.
CTIX news....
Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
BEVERLY, MA--(Marketwired - Mar 24, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the tenth cohort in the Company's Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has been completed. Patients in the tenth cohort were treated with 450 mg/m2 of Kevetrin with no adverse events reported.
Cellceutix has been advised that the tenth cohort is being included in the latest testing for the effect of Kevetrin on the biomarker p21, a key downstream protein and proxy for reactivation of the tumor suppressor protein p53. The data on p21 are expected to be received in mid-April.
Cellceutix had several options on the table moving forward with the trial. After meeting with the trial's Principal Investigator and Cellceutix consultants, the Company has decided to take dosing even higher due to the wide bandwidth of Kevetrin and enroll an eleventh cohort. The Safety Committee will meet in the coming weeks to determine the new dosing level, which, theoretically, could be increased up to 100 percent in a bid to define the maximum tolerated dose of Kevetrin.
LLBO de nuevo animándose 40 x 41
GAS
Está claro que las materias primas se han convertido en un producto especulativo, lo cual pagamos todos.